Valneva Stock Under Siege: Short Position, Share Overhang, and Revenue Slump Overshadow Lyme Vaccine Progress
13.06.2026 - 16:45:45 | boerse-global.de
Valneva’s stock closed at €2.27 on Friday, hovering just 6.5% above its 52-week low of €2.13 and nursing a staggering 41% year-to-date loss. The sell-off is not just a reflection of broader market sentiment — it is being fueled by two specific, immediate pressures that have little to do with the company’s long-awaited Lyme disease vaccine.
First, hedge fund Citadel Advisors has disclosed a fresh short position, adding to the bearish bets against the French biotech. Second, Valneva has registered nearly 31.8 million shares for potential resale by existing investors. This registration, filed under an F-3 shelf, creates a significant overhang that could weigh on the stock for weeks. Importantly, the company itself receives no proceeds from those sales. The sole exception is if all ABSA warrants from the 29 April 2026 private placement are exercised for cash — which would bring in up to €47 million. Whether that happens is uncertain.
The timing of these headwinds is particularly awkward. Management is currently in the middle of a transatlantic roadshow, presenting at the Oddo BHF Nextcap Forum, the Jefferies Global Healthcare Conference in New York, and two additional events in Paris. The centerpiece of every presentation is LB6V, the Lyme borreliosis vaccine candidate developed with Pfizer. Phase 3 data from the VALOR study showed 74.8% efficacy one day after the fourth dose and 73.2% one month later, with no safety concerns. Pfizer intends to file for FDA and EMA approval in autumn 2026, targeting a market launch in 2027.
Should investors sell immediately? Or is it worth buying Valneva?
But the market has shrugged. Even solid clinical data is not enough to overcome the immediate operational and financial strains. Valneva was forced to cut its full-year product sales guidance to €135–150 million, down from the earlier range of €145–160 million, citing weaker demand for travel vaccines. In response, the company announced a global workforce reduction of 10% to 15%. With 674 employees at the end of 2025, that translates to between 67 and 101 job cuts. Operating costs in 2026 are expected to fall 25% to 35% below 2025 levels.
Analysts remain cautiously optimistic, even as the technical picture deteriorates. Six analysts rate the stock a buy, one says sell. The average price target is €5.23 — more than double the current price. H.C. Wainwright’s Brandon Folkes reaffirmed his buy rating at the end of May. The 50-day moving average sits at €2.50, well above Friday’s close, and the relative strength index at 38.3 signals downward momentum without reaching oversold territory.
All eyes now turn to Valneva’s annual general meeting in Lyon at the end of June. Shareholders will look for concrete catalysts that can break the current spiral. Until then, the dual drag from the share registration and the short position is likely to keep the stock pinned near its lows — regardless of how well management pitches the Lyme vaccine story.
Ad
Valneva Stock: New Analysis - 13 June
Fresh Valneva information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
